Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke

Mayo Clinic Proceedings

Volumn 89, Issue 7, 2014, Pages 960-972

  Fugate, Jennifer E ^a   Rabinstein, Alejandro A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTIVITAMIN K; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; LABETALOL; NICARDIPINE; NITROPRUSSIDE SODIUM; PLACEBO;

ANGIONEUROTIC EDEMA; ANTICOAGULATION; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; CONTINUOUS INFUSION; CRANIECTOMY; DISEASE REGISTRY; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MEDICAL SOCIETY; NEUROIMAGING; ORTHOSTATIC HYPOTENSION; PATIENT CARE; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; PATIENT SELECTION; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84904744187     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.03.001     Document Type: Review

References (68)

1. Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke. 2011;42(8):2351-2355.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587.
3. Broderick JP, Palesch YY, Demchuk AM, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke [published correction appears in N Engl J Med. 2013;368(13): 1265]. N Engl J Med. 2013;368(10):893-903.
4. Ciccone A, Valvassori L, Nichelatti M; SYNTHESIS Expansion Investigators. SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke. Int J Stroke. 2011;6(3):259-265.
5. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274(13):1017-1025.
6. Hacke W, Kaste M, Fieschi C, et al; Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352(9136):1245-1251.
7. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.
8. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology. 2000;55(11):1649-1655.
9. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488.
10. Wahlgren N, Ahmed N, Dávalos A, et al; SITS-MOST Investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study [published correction appears in Lancet. 2007;369(9564):826]. Lancet. 2007;369(9558):275-282.
11. Kleindorfer D, de los Rios La Rosa F, Khatri P, Kissela B, Mackey J, Adeoye O. Temporal trends in acute stroke management. Stroke. 2013;44(6, suppl 1):S129-S131.
12. Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA. Utilization of intravenous thrombolysis is increasing in the United States. Int J Stroke. 2013;8(8):681-688.
13. de Los Ríos la Rosa F, Khoury J, Kissela BM, et al. Eligibility for intravenous recombinant tissue-type plasminogen activator within a population: the effect of the European Cooperative Acute Stroke Study (ECASS) III Trial. Stroke. 2012;43(6): 1591-1595.
14. Moradiya Y, Crystal H, Valsamis H, Levine SR. Thrombolytic utilization for ischemic stroke in US hospitals with neurology residency program. Neurology. 2013;81(23):1986-1995.
15. Hacke W, Donnan G, Fieschi C, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.
16. Wahlgren N, Ahmed N, Dávalos A, et al; SITS Investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008; 372(9646):1303-1309.
17. Ahmed N, Kellert L, Lees KR, Mikulik R, Tatlisumak T, Toni D; SITS Investigators. Results of intravenous thrombolysis within 4. 5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study. JAMA Neurol. 2013; 70(7):837-844.
18. Jauch EC, Saver JL, Adams HP Jr, et al; American Heart AssociationStroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
19. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial [published correction appears in Lancet. 2012;380(9843):730]. Lancet. 2012;379(9834):2352-2363.
20. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study; a randomized controlled trial. JAMA. 1999;282(21):2019-2026.
21. Safety of Intravenous Thrombolysis for Wake-up Stroke (Wake-Up Stroke). ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/NCT01183533?term= wake-up&rank=2. Updated May 7, 2013. Accessed February 22, 2014.
22. Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke (WAKE-UP). ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/ NCT01525290?term=wake+up+trial&rank=2. Updated May 27, 2013. Accessed February 22, 2014.
23. Saqqur M, Tsivgoulis G, Nicoli F, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and casecontrol studies [published online ahead of print April 22, 2013]. J Neuroimaging. http://dx.doi.org/10.1111/jon.12026.
24. Tsivgoulis G, Eggers J, Ribo M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke. 2010;41(2):280-287.
25. Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke (CLOTBUST-ER). ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/ NCT01098981?term=Clotbust+ER&rank=1. Updated July 11, 2013. Accessed February 22, 2014.
26. Pancioli AM, Adeoye O, Schmit PA, et al; CLEAR-ER Investigators. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke. 2013;44(9): 2381-2387.
27. Adams HP Jr, Effron MB, Torner J, et al; AbESTT-II Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial; Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39(1):87-99.
28. Study of the CombiPatentTherapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR). ClinicalTrials.gov website. http://clinicaltrials. gov/ct2/show/NCT01977456?term=Study+of+the+Combination+Therapy+of+Rt- PA+and+Eptifibatide+to+Treat+Acute+Ischemic+Stroke+%28CLEARFDR%29&rank=1. Updated December 5, 2013. Accessed February 22, 2014.
29. Demaerschalk BM, Miley ML, Kiernan TE, et al; STARR Coinvestigators. Stroke telemedicine [published correction appears in Mayo Clin Proc. 2010;85(4):400]. Mayo Clin Proc. 2009;84(1):53-64.
30. Rubin MN, Demaerschalk BM. The use of telemedicine in themanagement of acute stroke. Neurosurg Focus. 2014;36(1):E4.
31. MeyerBC,Raman R,Hemmen T, et al. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol. 2008;7(9):787-795.
32. Johnston SC. The economic case for new stroke thrombolytics. Stroke. 2010;41(10, suppl):S59-S62.
33. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36(11): 2500-2503.
34. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke: NINDS rt-PA Stroke Study Group. Neurology. 1998;50(4):883-890.
35. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306-313.
36. Weber JE, Ebinger M, Rozanski M, et al; STEMO-Consortium. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology. 2013;80(2):163-168.
37. Fugate JE, Rabinstein AA. Contraindications to intravenous rtPA for acute stroke: a critical reappraisal. Neurol Clin Pract. 2013; 3(3):177-185.
38. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507.
39. Chernyshev OY, Martin-Schild S, Albright KC, et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology. 2010;74(17):1340-1345.
40. Selim M, Kumar S, Fink J, Schlaug G, Caplan LR, Linfante I. Seizure at stroke onset: should it be an absolute contraindication to thrombolysis? Cerebrovasc Dis. 2002;14(1):54-57.
41. Winkler DT, Fluri F, Fuhr P, et al. Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke. 2009;40(4):1522-1525.
42. Zinkstok SM, Engelter ST, Gensicke H, et al. Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke. 2013;44(4):1080-1084.
43. Tsivgoulis G, Alexandrov AV, Chang J, et al. Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series. Stroke. 2011;42(6):1771-1774.
44. Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force, Levine SR, Khatri P, Broderick JP, et al; NINDS rt-PA Stroke Trial Investigators. Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria, part 1: Rapidly improving stroke symptoms. Stroke. 2013;44(9):2500-2505.
45. Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke. 2011;42(11):3110-3115.
46. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? an analysis of patient eligibility. Neurology. 2001;56(8):1015-1020.
47. Ahmed N, Wahlgren N, Brainin M, et al; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40(7):2442-2449.
48. Freeman WD, Chavez OS, Meschia J. Letter by Freeman et al regarding article, "Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial." Stroke. 2011;42(5):e375.
49. Takeuchi S, Wada K, Nawashiro H, et al. Decompressive craniectomy after intravenous tissue plasminogen activator administration for stroke. Clin Neurol Neurosurg. 2012;114(10): 1312-1315.
50. Albers GW, Thijs VN, Wechsler L, et al; DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60(5):508-517.
51. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38(8): 2279-2283.
52. Fugate JE, Kalimullah EA, Wijdicks EF. Angioedema after tPA: what neurointensivists should know. Neurocrit Care. 2012; 16(3):440-443.
53. Bruno A, Levine SR, Frankel MR, et al; NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002;59(5):669-674.
54. Kammersgaard LP, Jørgensen HS, Reith J, Nakayama H, Pedersen PM, Olsen TS. Short- and long-term prognosis for very old stroke patients: the Copenhagen Stroke Study. Age Ageing. 2004;33(2):149-154.
55. Gensicke H, Zinkstok SM, Roos YB, et al. IV thrombolysis andrenal function. Neurology. 2013;81(20):1780-1788.
56. Moulin T, Cattin F, Crépin-Leblond T, et al. Early CT signs in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome. Neurology. 1996;47(2): 366-375.
57. Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysisetreated ischemic stroke patients: the DRAGON score. Neurology. 2012;78(6):427-432.
58. Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. Aninteger-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology. 2012;78(24):1916-1922.
59. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology. 2013;80(1):21-28.
60. Flint AC, Faigeles BS, Cullen SP, et al; VISTA Collaboration. THRIVE score predicts ischemic stroke outcomes and thrombolytic hemorrhage risk in VISTA. Stroke. 2013;44(12):3365-3369.
61. Lou M, Safdar A, Mehdiratta M, et al. The HAT score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71(18):1417-1423.
62. Mazya M, Egido JA, Ford GA, et al; SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score [published correction appears in Stroke. 2012;43(9):e102]. Stroke. 2012;43(6):1524-1531.
63. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke. 2002;33(3):717-724.
64. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834): 2364-2372.
65. Guillan M, Alonso-Canovas A, Garcia-Caldentey J, et al. Off-labelintravenous thrombolysis in acute stroke. Eur J Neurol. 2012; 19(3):390-394.
66. Rabinstein A, Rundek T. Prediction of outcome after ischemic stroke: the value of clinical scores [editorial]. Neurology. 2013; 80(1):15-16.
67. French KF, White J, Hoesch RE. Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator. Neurocrit Care. 2012;17(1):107-111.
68. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099- 1107.